Shattuck Labs Share Price (NASDAQ: STTK)

$1.01

▲

0.15

(17.44%)

Last updated on August 18, 2025 at 11:36 PM IST

$₹

Check the interactive Shattuck Labs Stock chart to analyse performance

Shattuck Labs stock performance

as on August 18, 2025 at 11:36 PM IST

Today's Low:$0.89
Today's High:$1.06
$1.01
11.88%
Downside
Day's Volatility :16.04%
Upside
4.72%
52 Weeks Low:$0.69
52 Weeks High:$3.95
$1.01
31.47%
Downside
52 Weeks Volatility :82.48%
Upside
74.43%

Shattuck Labs Stock Returns

Period	Shattuck Labs Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-4.76%	2.3%	0.0%
6 Months	-20.63%	-5.8%	0.0%
1 Year	-71.35%	-10.9%	0.0%
3 Years	-70.33%	2.8%	-11.6%

Shattuck Labs Inc. Key Stats

Check Shattuck Labs key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$1.0
Open	$0.89
Today's High	$1.02
Today's Low	$0.9701
Market Capitalization	$47.9M
Today's Volume	$1.8M
52 Week High	$3.95
52 Week Low	$0.69215
Revenue TTM	$3.0M
EBITDA	$-61.0M
Earnings Per Share (EPS)	$-1.21
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-73.39%

Stock Returns calculator for Shattuck Labs Stock including INR - Dollar returns

The Shattuck Labs stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Shattuck Labs investment value today

Current value as on today

₹33,013

Returns

₹66,987

(-66.99%)

Returns from Shattuck Labs Stock

₹71,060 (-71.06%)

Dollar Returns*

₹4,073 (+4.07%)

Indian investors sentiment towards Shattuck Labs Stock

983.33%

Period: Jul 18, 2025 to Aug 17, 2025. Change in 30 Days versus previous period

Investment in Shattuck Labs Shares from India has grown by 983.33% over the past 30 days, indicating increased transactional activity.

338%

Period: Jul 18, 2025 to Aug 17, 2025. Change in 30 Days versus previous period

Search interest for Shattuck Labs Stock from India on INDmoney has increased by 338% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Shattuck Labs Inc.

Name
Holdings %
Name
Holdings %
Prosight Management, LP
13.86%
Redmile Group, LLC
11.56%
Adage Capital Partners Gp LLC
9.76%
BlackRock Inc
5.44%
Vanguard Group Inc
4.48%
Clark Estates Inc
3.08%

Analyst Recommendation on Shattuck Labs Stock

Rating

Trend

Buy

91%Buy

8%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Shattuck Labs(by analysts ranked 0 to 5 stars)

Shattuck Labs Share Price Target

What analysts predicted

Upside of 44.55%

Target:

$1.46

Current:

$1.01

Shattuck Labs share price target is $1.46, a slight Upside of 44.55% compared to current price of $1.01 as per analysts' prediction.

Shattuck Labs Stock Insights

Price Movement
In the last 7 days, STTK stock has moved up by 35.3%
Decreasing Revenue
Revenue is down for the last 2 quarters, 34.70M → 14.49M (in $), with an average decrease of 58.2% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -18.67M → -12.45M (in $), with an average increase of 23.2% per quarter
STTK vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 67.4% return, outperforming this stock by 137.6%
STTK vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 100.9% return, outperforming this stock by 172.3%
Price to Sales
ForSTTK every $1 of sales, investors are willing to pay $16.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.6 for every $1 of sales.

Shattuck Labs Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$9.9M	↓ 55.94%
Net Income	$-23.9M	↑ 223.27%
Net Profit Margin	-241.56%	↓ 208.64%

	FY20	Y/Y Change
Revenue	$9.9M	↑ 0.48%
Net Income	$-35.4M	↑ 48.37%
Net Profit Margin	-356.71%	↓ 115.15%

	FY21	Y/Y Change
Revenue	$30.0M	↑ 202.16%
Net Income	$-45.0M	↑ 26.92%
Net Profit Margin	-149.83%	↑ 206.88%

	FY22	Y/Y Change
Revenue	$652.0K	↓ 97.83%
Net Income	$-100.6M	↑ 123.6%
Net Profit Margin	-15.4K%	↓ 15273.64%

	FY23	Y/Y Change
Revenue	$1.7M	↑ 154.14%
Net Income	$-87.3M	↓ 13.19%
Net Profit Margin	-5.3K%	↑ 10155.03%

	FY24	Y/Y Change
Revenue	$5.7M	↑ 245.26%
Net Income	$-75.4M	↓ 13.62%
Net Profit Margin	-1.3K%	↑ 3950.31%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q1 FY24	Q/Q Change
Revenue	$1.1M	↑ 56.16%
Net Income	$-18.5M	↑ 4.62%
Net Profit Margin	-1.7K%	↑ 817.62%

	Q2 FY24	Q/Q Change
Revenue	$1.6M	↑ 44.3%
Net Income	$-21.6M	↑ 16.47%
Net Profit Margin	-1.3K%	↑ 320.08%

	Q3 FY24	Q/Q Change
Revenue	$3.0M	↑ 86.26%
Net Income	$-16.7M	↓ 22.63%
Net Profit Margin	-556.39%	↑ 783.08%

	Q4 FY24	Q/Q Change
Revenue	$34.7M	↑ 1057.99%
Net Income	$-18.7M	↑ 12.02%
Net Profit Margin	-53.82%	↑ 502.57%

	Q1 FY25	Q/Q Change
Revenue	$14.5M	↓ 58.24%
Net Income	$-13.7M	↓ 26.64%
Net Profit Margin	-94.55%	↓ 40.73%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-19.1M	↑ 708.2%

	FY20	Y/Y Change
Profit	$9.9M	↓ 151.97%

	FY21	Y/Y Change
Profit	$28.6M	↑ 188.27%

	FY22	Y/Y Change
Profit	$652.0K	↓ 97.72%

	FY23	Y/Y Change
Profit	$-2.4M	↓ 465.8%

	FY24	Y/Y Change
Profit	$5.7M	↓ 339.87%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q1 FY24	Q/Q Change
Profit	$141.0K	↓ 152.81%

	Q2 FY24	Q/Q Change
Profit	$647.0K	↑ 358.87%

	Q3 FY24	Q/Q Change
Profit	$3.0M	↑ 363.21%

	Q4 FY24	Q/Q Change
Profit	$14.5M	↑ 383.55%

	Q1 FY25	Q/Q Change
Profit	$-936.0K	↓ 106.46%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-21.0M	↑ 203.85%
Investing Cash Flow	$-3.6M	↓ 88.0%
Financing Cash Flow	$-64.0K	↓ 100.18%

	FY20	Y/Y Change
Operating Cash Flow	$-33.7M	↑ 60.47%
Investing Cash Flow	$-146.3M	↑ 3973.55%
Financing Cash Flow	$330.9M	↓ 517078.12%

	FY21	Y/Y Change
Operating Cash Flow	$-57.1M	↑ 69.69%
Investing Cash Flow	$-10.4M	↓ 92.86%
Financing Cash Flow	$1.9M	↓ 99.42%

	FY22	Y/Y Change
Operating Cash Flow	$-94.5M	↑ 65.45%
Investing Cash Flow	$49.4M	↓ 573.41%
Financing Cash Flow	$171.0K	↓ 91.14%

	FY23	Y/Y Change
Operating Cash Flow	$-81.2M	↓ 14.04%
Investing Cash Flow	$110.9M	↑ 124.24%
Financing Cash Flow	$48.6M	↑ 28330.41%

	FY24	Y/Y Change
Operating Cash Flow	$-60.5M	↓ 25.5%
Investing Cash Flow	$-8.5M	↓ 107.68%
Financing Cash Flow	$787.0K	↓ 98.38%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-16.2M	↓ 16.78%
Investing Cash Flow	$-33.3M	↓ 159.58%
Financing Cash Flow	$-184.0K	↓ 100.38%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-10.9M	↓ 32.44%
Investing Cash Flow	$-5.4M	↓ 83.73%
Financing Cash Flow	$1.0M	↓ 654.35%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-16.1M	↑ 47.15%
Investing Cash Flow	$-821.0K	↓ 84.84%
Financing Cash Flow	$23.0K	↓ 97.75%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-17.4M	↑ 8.12%
Investing Cash Flow	$31.0M	↓ 3875.88%
Financing Cash Flow	$-72.0K	↓ 413.04%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-12.0M	↓ 30.73%
Investing Cash Flow	$15.6M	↓ 49.68%
Financing Cash Flow	$-57.0K	↓ 20.83%

Shattuck Labs Technicals Summary

Sell

Neutral

Buy

Shattuck Labs is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Shattuck Labs Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Shattuck Labs Inc.	30.23%	-20.63%	-71.35%	-70.33%	-94.83%
Regeneron Pharmaceuticals, Inc.	6.39%	-14.65%	-51.51%	-6.14%	-7.82%
Beone Medicines Ltd	10.08%	34.96%	66.94%	83.8%	36.85%
Vertex Pharmaceuticals Incorporated	-14.33%	-15.0%	-19.52%	31.35%	45.44%
Alnylam Pharmaceuticals, Inc.	40.06%	79.56%	63.55%	107.86%	227.15%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Shattuck Labs Inc.	NA	NA	NA	-0.73	-0.73	-0.42	NA	1.19
Regeneron Pharmaceuticals, Inc.	14.62	14.62	1.19	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.33	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.94	27.94	0.58	18.04	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Shattuck Labs Inc.	Buy	$47.9M	-94.83%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$61.5B	-7.82%	14.62	31.37%
Beone Medicines Ltd	NA	$38.8B	36.85%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.7B	45.44%	27.94	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$58.0B	227.15%	NA	-12.96%

About Shattuck Labs Inc.

Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease; and a series of bispecific antibodies targeting DR3 and other clinically validated targets. In addition, the company is involved in the advancement of its lead TRIM7 inhibitors through preclinical development as future internal pipeline candidates in oncology. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Organization	Shattuck Labs
Employees	44
CEO	Dr. Taylor H. Schreiber M.D., Ph.D.
Industry	Health Technology

Key Management of Shattuck Labs Inc.

Name	Title
Dr. Taylor H. Schreiber M.D., Ph.D.	Co-Founder, CEO & Director
Mr. Andrew R. Neill M.B.A.	Chief Financial Officer
Dr. Arunthathy Nirmalini Pandite M.B.A., M.D.	Chief Medical Officer
Dr. Abhinav A. Shukla Ph.D.	Chief Technical Officer
Dr. Stephen Stout J.D., Ph.D.	General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer
Ms. Casi DeYoung	Chief Business Officer
Dr. Thomas Lampkin Pharm.D.	Senior Vice President of Regulatory Affairs
Mr. George Fromm Ph.D.	Co-Chief Scientific Officer
Mr. Suresh de Silva Ph.D.	Co-Chief Scientific Officer
Ms. Kelli Collin M.S.	Senior Vice President of Quality

Important FAQs about investing in STTK Stock from India :

What is Shattuck Labs share price today?

Shattuck Labs share price today is $1.01 as on August 18, 2025 at 11:36 PM IST at the close of the market. Shattuck Labs share today touched a day high of $1.06 and a low of $0.89.

What is the 52 week high and 52 week low for Shattuck Labs share?

Shattuck Labs share touched a 52 week high of $3.95 and a 52 week low of $0.69. Shattuck Labs stock price today, August 18, 2025 at 11:36 PM IST is trending at $1.01, lower by 74.43% versus the 52 week high.

How to invest in Shattuck Labs Stock (STTK) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Shattuck Labs on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Shattuck Labs Shares that will get you 1.4851 shares as per Shattuck Labs share price of $1.01 per share as on August 18, 2025 at 11:36 PM IST.

What is the minimum amount required to buy Shattuck Labs Stock (STTK) from India?

Indian investors can start investing in Shattuck Labs (STTK) shares with as little as ₹87.3775 or $1 (as of August 18, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹873.77 in Shattuck Labs stock (as per the Rupee-Dollar exchange rate as on August 18, 2025). Based on Shattuck Labs share’s latest price of $1.01 as on August 18, 2025 at 11:36 PM IST, you will get 9.9010 shares of Shattuck Labs. Learn more about fractional shares .

What are the returns that Shattuck Labs has given to Indian investors in the last 5 years?

Shattuck Labs stock has given -94.83% share price returns and 16.91% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?